Načítá se...
Characterization of T‐DM1‐resistant breast cancer cells
The development of targeted therapies has drastically improved the outcome of patients with different types of cancer. T‐DM1 (trastuzumab‐emtansine) is an antibody‐drug conjugate used for the treatment of HER2‐positive breast cancer combining the FDA approved mAb (monoclonal antibody) trastuzumab an...
Uloženo v:
| Vydáno v: | Pharmacol Res Perspect |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7314699/ https://ncbi.nlm.nih.gov/pubmed/32583565 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.617 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|